While the decline in JNJ’s share price on a revenue miss was expected, it does not tell the whole story. Johnson & Johnson has long been considered to be one of the pillars of the Dow 30 Industrial composite and the United States’ best-managed health-care company. Up until 2009, Johnson & Johnson had increased its annualized revenue for the past 35 consecutive years. That has all changed because the company’s revenue has declined for the third straight quarter, and revenue for its calendar year ending Dec 31 is expected to decline.
To discover what this means for the Dow overall and to read Michael Markowski’s full article, click here.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine.
